Recently, immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors, which enhance anti-tumor activity, has revolutionized the therapeutic strategy for multiple malignancies (6). This evidence concerns the gene PDCD1 and neoplasm.